Want to see MRVI full AI Analyst Report?
Top Page
Maravai Lifesciences Holdings
(NASDAQ:MRVI)
Select Model
Select Model
Rating:55Neutral
Price Target:
$6.50
▼(-3.85% Downside)
Action:Reiterated
Date:08/07/26
MRVI scores as moderate: the earnings call was a clear positive driver (raised adjusted EBITDA outlook and major margin expansion expectations), and leverage has improved. Offsetting this, current financial performance remains weak due to significant losses and negative operating/free cash flow, while valuation is constrained by negative earnings and no stated dividend support. Technicals are mixed, with longer-term trend support but softer near-term momentum.
Positive Factors
Sustained Gross Margin Expansion
A durable shift to higher-margin products (notably GMP consumables and CleanCap analogs) drove a large gross-margin expansion. Sustained 50%+ adjusted gross margins improve cash generation potential per revenue dollar and create buffer for reinvestment and profitability as volumes scale.
Negative Factors
Persistent GAAP Losses
Despite operational progress, continued GAAP losses indicate the company has not yet converted margin gains into bottom-line profitability. Ongoing net losses pressure equity returns, limit retained-capital deployment, and keep reliance on external financing or sustained margin improvement for profitable scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Gross Margin Expansion
A durable shift to higher-margin products (notably GMP consumables and CleanCap analogs) drove a large gross-margin expansion. Sustained 50%+ adjusted gross margins improve cash generation potential per revenue dollar and create buffer for reinvestment and profitability as volumes scale.
Read all positive factors
Maravai Lifesciences Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyMaravai Lifesciences Holdings (MRVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.70B
Dividend YieldN/A
Average Volume (3M)3.10M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-15.35%
EPS Growth37.09%
CountryUS
Employees435
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding147,506,160
10 Day Avg. Volume3,409,671
30 Day Avg. Volume3,104,575
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.88Price Target Upside-13.09% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$210.47M
Maravai Lifesciences Holdings Business Overview & Revenue Model
Company Description
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse prod...
How the Company Makes Money
Maravai makes money primarily by selling high-value life science reagents and providing testing and supporting services to biopharma companies, diagnostic developers, academic/government labs, and contract manufacturers. Key revenue streams includ...
Maravai Lifesciences Holdings Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call conveyed strong operational progress and financial improvement: revenue growth, large margin expansion, significantly improved adjusted EBITDA, record customer additions, product launches and patent wins, plus a materially strengthened balance sheet via refinancing. The primary negatives are that GAAP losses persist, certain businesses (CDMO and some new products) remain lumpy or early-stage, and timing risk exists around large program-driven orders and GMP conversions. On balance, the call emphasized accelerating commercial execution and durable margin improvement, with management maintaining prudent revenue guidance while raising confidence in profitability.Positive Updates
Quarterly Revenue Growth
Total revenue of $51.4 million in Q2 2026, representing 9% year-over-year growth versus prior-year period.
Negative Updates
GAAP Net Loss Remains
GAAP net loss before noncontrolling interest of $21.6 million in Q2 (improved versus $69.8 million prior-year), and basic/diluted GAAP loss per share of $0.08; adjusted EPS remains a loss (adjusted EPS loss $0.02 vs. $0.08 loss prior year).
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Total revenue of $51.4 million in Q2 2026, representing 9% year-over-year growth versus prior-year period.
Read all positive updates
Company Guidance
Management reiterated 2026 revenue guidance of $205–$215 million (growth of ~10%–16% vs. 2025) while raising full‑year adjusted EBITDA to $33–$35 million (an implied year‑over‑year improvement of roughly $64–$66 million), and now expects gross margin expansion of greater than 1,400 basis points; they expect TriLink growth in the high‑teens and Cygnus growth in the low‑ to mid‑single digits, noted mRNA (excluding COVID) is ~35% of expected 2026 revenue, CDMO <5% and specialty chemistry a bit over 20%, reminded investors COVID CleanCap was $14.3 million in Q1 (about 7% of midpoint guidance), said GMP ModTail orders are not assumed in 2H (expected revenue impact in 2027), highlighted first enzyme GMP order shipped, and cited a stronger balance sheet with $70.1 million cash and ~$147.1–$150 million debt after refinancing with maturities extended to 2032 as reasons for their prudent but more confident profitability outlook.Maravai Lifesciences Holdings Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.73M | 185.74M | 259.19M | 288.94M | 883.00M | 799.24M |
| Gross Profit | 59.37M | 33.39M | 108.31M | 140.20M | 714.04M | 658.68M |
| EBITDA | -103.91M | -147.11M | -156.92M | 712.41M | 609.99M | 585.78M |
| Net Income | -104.56M | -130.77M | -144.85M | -119.03M | 220.21M | 182.04M |
Balance Sheet | ||||||
| Total Assets | 713.22M | 770.58M | 1.01B | 1.49B | 2.28B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 165.92M | 216.89M | 322.40M | 574.96M | 632.14M | 551.27M |
| Total Debt | 270.88M | 35.58M | 376.69M | 610.97M | 585.26M | 575.22M |
| Total Liabilities | 344.13M | 397.87M | 431.04M | 697.57M | 1.38B | 1.37B |
| Stockholders Equity | 211.56M | 212.38M | 325.29M | 416.75M | 545.22M | 315.50M |
Cash Flow | ||||||
| Free Cash Flow | -51.87M | -70.72M | -22.19M | 60.67M | 518.89M | 353.72M |
| Operating Cash Flow | -39.52M | -57.57M | 7.46M | 126.22M | 535.98M | 368.57M |
| Investing Cash Flow | -12.71M | -31.41M | -24.32M | -122.31M | -267.61M | 105.66M |
| Financing Cash Flow | -66.83M | -16.50M | -235.71M | -61.09M | -187.50M | -159.05M |
Maravai Lifesciences Holdings Technical Analysis
Positive
6.76
Price Trends
5.91
Positive
4.74
Positive
4.09
Positive
Market Momentum
0.13
Positive
46.10
Neutral
13.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 6.76 is above the 20-day moving average (MA) of 6.72, above the 50-day MA of 5.91, and above the 200-day MA of 4.09, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 46.10 is Neutral, neither overbought nor oversold. The STOCH value of 13.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.
Maravai Lifesciences Holdings Risk Analysis
Maravai Lifesciences Holdings disclosed 74 risk factors in its most recent earnings report. Maravai Lifesciences Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maravai Lifesciences Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.92B | -30.51 | -19.83% | ― | ― | -15.44% | |
56 Neutral | $799.86M | -2.69 | -141.95% | ― | 5.37% | -60.20% | |
55 Neutral | $1.70B | -9.06 | -33.10% | ― | -15.35% | 37.09% | |
55 Neutral | $4.10B | -11.99 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.04B | -2.00 | 1870.38% | ― | -50.80% | 14.80% | |
44 Neutral | $1.16B | -4.39 | -45.27% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
MRVI
Maravai Lifesciences Holdings
6.23
4.03
183.18%
KURA
Kura Oncology
9.57
4.03
72.74%
IMTX
Immatics
9.65
3.47
56.15%
RLAY
Relay Therapeutics
19.77
16.55
513.98%
IVA
Inventiva
4.80
1.22
34.08%
GHRS
GH Research
30.27
17.86
143.92%
Maravai Lifesciences Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Maravai LifeSciences Refinances Debt, Extends Credit Facilities
Positive
Jun 3, 2026
On June 2, 2026, Maravai LifeSciences subsidiaries Maravai Intermediate Holdings and Maravai Topco entered into a new credit agreement that establishes a $150 million term loan and a $30 million revolving credit facility, both maturing on June 2, ...
Executive/Board ChangesShareholder Meetings
Maravai Lifesciences Shareholders Back Board, Pay, Auditor
Positive
May 29, 2026
On May 26, 2026, Maravai LifeSciences Holdings, Inc. held its 2026 Annual Meeting of Shareholders, where 236,082,968 of 258,180,170 outstanding common shares were represented, establishing a quorum and reflecting strong shareholder participation. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.